Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VYR-102
- Development stage
- Preclinical
- Lead developer
- Vyripharm International
- Modality
- Hydrogel Systems → Drug Delivery Systems
01
Overview
VYR-102 is a preclinical-stage therapeutic candidate being developed by Vyripharm International for the treatment of addiction. It utilizes a specialized hydrogel-based drug delivery system designed to provide controlled or sustained release of therapeutic agents. The program aims to address substance use disorders by optimizing the delivery profile of addiction-related medications, potentially improving patient compliance and treatment outcomes. As of the latest pipeline updates, the specific active pharmaceutical ingredient (API) incorporated into the hydrogel has not been publicly disclosed, and the program remains in the preclinical phase of development.
Beyond the preview
Go deeper on VYR-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VYR-102.